Ligand Pharmaceuticals Incorporated functions as a global biopharmaceutical entity, concentrating on the advancement and licensing of pharmaceutical assets. Its diverse portfolio includes commercial products targeting a wide array of serious health conditions. Key therapeutic offerings comprise Kyprolis and Evomela for the treatment of multiple myeloma, alongside Rylaze, an asparaginase formulation designed for both adult and pediatric patients battling acute lymphoblastic leukemia or lymphoblastic lymphoma. The company also provides Filspari, a dual endothelin and angiotensin II receptor antagonist, currently being developed for specific rare kidney diseases and as a non-immunosuppressive treatment for immunoglobulin A nephropathy. Further extending its reach, Ligand's portfolio features a teriparatide injection product for osteoporosis management. In the vaccine space, Vaxneuvance aims to prevent invasive disease caused by Streptococcus pneumoniae serotypes, while Pneumosil offers a pneumococcal conjugate vaccine primarily for children. A notable advancement is TZIELD, a CD3-directed antibody indicated to postpone the progression to Stage 3 type 1 diabetes in adults and children aged eight years and older who have Stage 2 T1D. Many of Ligand's solutions leverage its proprietary Captisol technology, enhancing drug formulations. Examples include Nexterone (a Captisol-enabled amiodarone), Zulresso (a Captisol-enabled brexanolone for postpartum depression), and Veklury, an antiviral treatment for moderate or severe COVID-19. The Captisol platform also supports Noxafil-IV, an IV formulation of posaconazole. Additional products in their repertoire address various indications such as post-menopausal symptoms (Duavee), autoimmune diseases (Exemptia), breast cancer (Vivitra), and other conditions through Bryxta and Zybev. Beyond its licensed therapies, Ligand also directly markets its Captisol materials. The company fosters strategic alliances, licenses, and business relationships with prominent pharmaceutical firms, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Ligand Pharmaceuticals Incorporated, founded in 1987, maintains its headquarters in Jupiter, Florida.
What is Ligand Pharmaceuticals stock price today?▼
The current price of LGNYZ is $0.05 USD — it has decreased by -5.76% in the past 24 hours. Watch Ligand Pharmaceuticals stock price performance more closely on the chart.
What is Ligand Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ligand Pharmaceuticals stocks are traded under the ticker LGNYZ.
What is Ligand Pharmaceuticals market cap?▼
Today Ligand Pharmaceuticals has the market capitalization of 897,345
When is the next Ligand Pharmaceuticals earnings date?▼
Ligand Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Ligand Pharmaceuticals earnings last quarter?▼
LGNYZ earnings for the last quarter are 1.63 USD per share, whereas the estimation was 1.82 USD resulting in a -10.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ligand Pharmaceuticals revenue for the last year?▼
Ligand Pharmaceuticals revenue for the last year amounts to 536.17M USD.
What is Ligand Pharmaceuticals net income for the last year?▼
LGNYZ net income for the last year is 248.91M USD.
Does Ligand Pharmaceuticals pay dividends?▼
Yes, LGNYZ dividends are paid semi-annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 9.07%.
How many employees does Ligand Pharmaceuticals have?▼
As of June 24, 2026, the company has 68 employees.
In which sector is Ligand Pharmaceuticals located?▼
Ligand Pharmaceuticals operates in the Other sector.
When did Ligand Pharmaceuticals complete a stock split?▼
The last stock split for Ligand Pharmaceuticals was on November 19, 2010 with a ratio of 1:6.
Where is Ligand Pharmaceuticals headquartered?▼
Ligand Pharmaceuticals is headquartered in Jupiter, United States.